Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

gilead sciences switzerland sàrl - sacituzumabum govitecanum - pulver für ein konzentrat zur herstellung einer infusionslösung - praeparatio cryodesiccata: sacituzumabum govitecanum 180 mg, acidum morpholinoethansulfonicum, trehalosum dihydricum, polysorbatum 80, pro vitro. - mammakarzinom - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

astellas pharma ag - enfortumabum vedotinum - pulver für ein konzentrat zur herstellung einer infusionslösung - praeparatio cryodesiccata: enfortumabum vedotinum 20 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, polysorbatum 20, pro vitro. - urothelkarzinom - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

astellas pharma ag - enfortumabum vedotinum - pulver für ein konzentrat zur herstellung einer infusionslösung - praeparatio cryodesiccata: enfortumabum vedotinum 30 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, polysorbatum 20, pro vitro. - urothelkarzinom - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - amivantamabum - konzentrat zur herstellung einer infusionslösung - amivantamabum 350 mg, histidinum, histidini hydrochloridum monohydricum, saccharum, polysorbatum 80, dl-methioninum, dinatrii edetas, aqua ad iniectabile q.s. ad solutionem pro 7.0 ml corresp. natrium 17 µg. - nicht-kleinzelliges lungenkarzinom (nsclc) - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

incyte biosciences international sàrl - tafasitamabum - pulver für ein konzentrat zur herstellung einer infusionslösung - praeparatio cryodesiccata: tafasitamabum 200 mg, natrii citras dihydricus corresp. natrium 7.4 mg, acidum citricum monohydricum, trehalosum dihydricum, polysorbatum 20, pro vitro. - lymphome diffus à grandes cellules b (dlbcl) - biotechnologika

Europäische Union - Deutsch - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - antineoplastische mittel - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Europäische Union - Deutsch - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - lymphom, follikulär - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - belantamabum mafodotinum - pulver für ein konzentrat zur herstellung einer infusionslösung - praeparatio cryodesiccata: belantamabum mafodotinum 100 mg, natrii citras dihydricus, acidum citricum, trehalosum dihydricum, dinatrii edetas, polysorbatum 80, pro vitro corresp. natrium 3.15 mg. - multiples myelom - biotechnologika

Europäische Union - Deutsch - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastische mittel - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Europäische Union - Deutsch - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - karzinom, nicht kleinzellige lunge - antineoplastische mittel - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.